Skip to content

UFP科技

US · UFPT #2677 按市值排名 上市于 1970
291.67 -5.52 -1.86%
实时 - 追踪5344个代码 - 心跳于463秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
211.67 合理价值 ≈ 275.87 340.07
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为211.67-340.07。
  • 当前价格比按平均倍数计算的合理价值(275.87)高5.7%。

估值 各估值倍数与自身5年区间的对比

市净率 5.07 高于历史水平 第71百分位
5年平均 4.64 · 在Medical Devices中排名第90/125
市盈率 32.74 处于历史正常水平 第67百分位
5年平均 31.53 · 前瞻 30.01 · 在Medical Devices中排名第25/38
市销率 3.71 高于历史水平 第76百分位
5年平均 3.36 · 前瞻 3.49 · 在Medical Devices中排名第85/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
UFP科技 (UFPT) 2.26B 31.53 4.89 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值279.93 经济护城河Narrow 不确定性High

当前股价高于晨星合理价值估算4.0%。

合理价值

UFP Technologies Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% premium over our quantitative fair value estimate of $279.93 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 19.9%, which falls in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 26.9%, for example, ranks in the bottom 30% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

UFP科技 讨论区 0 条评论

发表评论